Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical Trials.

Presence of more than 0% but less than 4% maxVAF versus 0% maxVAF was associated with poorer survival (11.6 vs 16.0 months, respectively; HR, 1.27 0.871–1.86; p = 0.214), though this did not reach statistical significance ( Fig. 3 , Supplementary Table S6).

also in 111,027 other papers